Astellas

Astellas to close Urogenix, shift urology research to Japan

Monday, August 6, 2012 02:09 PM

Astellas Pharma has decided to close Urogenix, an Astellas subsidiary and Durham, N.C.-based research facility focusing on drug discovery in the field of urology.

More... »

FDA approves Myrbetriq for overactive bladder

Friday, June 29, 2012 12:04 PM

The FDA has approved Astellas Pharma’s Myrbetriq (mirabegron) to treat adults with overactive bladder.

More... »

Astellas, DNDi collaborate on drug discovery research treating NTDs

Wednesday, June 13, 2012 09:08 AM

Astellas Pharma of Tokyo, Japan, and the Drugs for Neglected Diseases initiative (DNDi), a not-for-profit R&D organization focused on neglected diseases, have formed a drug discovery research collaboration for leishmaniasis, Chagas disease and sleeping sickness — three neglected tropical diseases (NTDs) which together affect nearly 10 million people worldwide.

More... »

Astellas opens new headquarters in Illinois, creates 150 jobs

Tuesday, June 5, 2012 08:01 AM

Astellas Pharma U.S., subsidiary of Tokyo-based Astellas Pharma, has opened its new headquarters in Glenview, Ill., serving the Americas.

More... »

Recipients of 2012 SAFE-Biopharma Digi Award named

Monday, April 30, 2012 04:52 PM

Recipients have been selected for the 2012 SAFE-BioPharma Digi Award, recognizing innovative uses of the global SAFE-BioPharma digital identity and digital signature standard and the institutions and individuals contributing to broader understanding of its benefits. Recipients included: Astellas, Bristol-Myers Squibb and representatives of two U.S. government entities.

More... »

Astellas and Drais to develop Astellas compound through Telsar

Friday, April 27, 2012 02:13 PM

Astellas Pharma of Tokyo and Drais Pharmaceuticals of Bridgewater, N.J., have entered into a uniquely structured partnership to develop and commercialize an Astellas compound currently in phase IIa study.

More... »

INC Research, Astellas form multi-year development alliance

Wednesday, April 18, 2012 11:04 AM

INC Research, a therapeutically focused CRO, has entered into a Functional Service Provider (FSP) alliance with Astellas Pharma to drive global consistency, save time and reduce costs for multiple clinical development programs across several therapeutic areas.

More... »

Astellas and Optimer collaborate on fidaxomicin in Japan

Monday, April 2, 2012 03:57 PM

San Diego-based Optimer Pharmaceuticals and Tokyo-based Astellas Pharma have formed an exclusive collaboration and license agreement to develop and commercialize fidaxomicin tablets in Japan for the treatment of Clostridium difficile infection (CDI) affecting the colon.

More... »

Three studies show positive results in overactive bladder

Friday, March 2, 2012 06:06 AM

Astellas Pharma Europe, subsidiary of Tokyo-based Astellas Pharma, has reported results from three separate clinical trials that further support the efficacy and tolerability of mirabegron for overactive bladder (OAB).

More... »

Astellas names Kremer senior VP of global medical affairs

Wednesday, February 29, 2012 06:02 AM

Tokyo-based Astellas Pharma has named Charlotte M. E. Kremer, M.D., senior vice president of Global Medical Affairs (GMA), one of the company's newest organizations.

More... »